Gustavo Alva, MD, DFAPA

After 40 years, Psychiatric Times is still your go-to resource for all things psychiatry. Just ask our Mood Disorders Section Editor.

While the removal of the REMS requirement can be liberating, appropriate monitoring for patients with schizophrenia is still of the utmost importance.

Our Mood Disorders Section Editor shares what treatments in the pipeline he is most excited about, including kappa opioid receptor antagonists.

Our Mood Disorders Section Editor shares his thoughts on this year's biggest clinical trial successes and failures.

What are the most pressing issues facing psychiatry? Gustavo Alva, MD, FAPA, shares his thoughts.

Celebrate our 40th anniversary with Gustavo Alva, MD, FAPA, our Mood Disorders Section Editor.

Here are 10 things to consider when treating a patient with mood disorders.

Check out these top 10 best practices for treating patients with mood disorders.

Our Mood Disorders Section Editor discusses the disorder in honor of World Bipolar Day.

The Psychiatric Times Special Report on Treatment-Resistant Depression includes expert discussions on how clinicians can manage major depressive disorder and treatment-resistant depression in patients who do not achieve wellness right away.

Psychiatric Times chats with new Mood Disorders Section Editor Gus Alva, MD, about his new role, his interest in mood disorders, and his love of psychiatry.

Clinicians wrap up their discussion on novel, rapid-acting agents for major depressive disorder (MDD) with key insights and takeaways for providers.

Clinicians expand their discussion with a second patient case, highlighting similarities and differences between cases, and particular treatment algorithms that may be helpful.

Experts continue their discussion of the first patient case, explaining how glutamate-modulating therapies could help improve his symptoms and outcomes.

Experts use a major depressive disorder (MDD) patient case to provide clinical insights on managing MDD, and how they would educate patients about their condition.

Clinicians wrap up their discussion of three new agents approved for the treatment of major depressive disorder (MDD).

Clinicians continue their discussion of three new agents approved for the treatment of major depressive disorder (MDD).

Clinicians begin their review of three new agents approved for the treatment of major depressive disorder (MDD).

Experts highlight the current and prospective therapies for patients with MDD, highlighting key similarities and differences in patient pathophysiology, drug onset of action, and overall therapeutic limitations.

Experts discuss the impact of targeting glutamate receptors, highlighting its positive effects for patients with anhedonia.

Experts discuss the need to review current clinical guidelines in light of the need for rapid-acting treatment, especially as first-line treatments for some patients.

Clinicians discuss the particular benefits of rapid-acting agents for major depressive disorder (MDD), highlighting the gap glutamate-modulating agents fill in targeted therapies.

Experts continue their discussion on the role of glutamate receptors, explaining their role in stimulating neuroplasticity and neurogenesis.

Clinicians discuss the effects of glutamate modulation on neuroplasticity, memory, and cognitive function, highlighting their role in improving overall wellness for their patients.

Experts highlight the role of NMDA and AMPA receptors in major depressive disorder (MDD) and how new therapies are targeting novel mechanisms of action.

Clinicians discuss past treatment options compared to novel glutamate-modulating agents, highlighting their rapid onset of symptom relief.

Experts discuss the significance of glutamate in major depressive disorder, highlighting its links to neuroplasticity and stress.

Carmen Kosicek, MSN, PMHNP-BC; Charles Montano, MD; and Gus Alva, MD, DFAPA, provide take-home messages for the management of patients with MDD and other depressive disorders.

Experts in psychiatry examine emerging agents and unmet needs for the management of MDD.

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, comment on the impact of various classes of MDD treatments on time to achieve goals and/or response.